作者
Oliver Sartor, Johann De Bono, Kim N Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Luke T Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H Park, Tomasz M Beer, Alison Armour, Wendy J Pérez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A Messmann, Michael J Morris, Bernd J Krause
发表日期
2021/9/16
期刊
New England Journal of Medicine
卷号
385
期号
12
页码范围
1091-1103
出版商
Massachusetts Medical Society
简介
Background
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Methods
We conducted an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor–pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 (68Ga)–labeled PSMA-11 positron-emission tomographic–computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol …
引用总数
学术搜索中的文章
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann… - New England Journal of Medicine, 2021